NRG Oncology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.nrgoncology.org
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- Conditions
- Cognitive ImpairmentsBreast Cancer
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 386
- Registration Number
- NCT05896189
- Locations
- 🇺🇸
Reid Health, Richmond, Indiana, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Conditions
- Breast Cancer
- Interventions
- Drug: Ovarian Function Suppression + Aromatase InhibitorDrug: Adjuvant Chemotherapy + Ovarian Function Suppression
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 3960
- Registration Number
- NCT05879926
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Radiation: Standard of Care Adjuvant Breast RadiationDrug: Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 1300
- Registration Number
- NCT05705401
- Locations
- 🇺🇸
Kent Hospital, Warwick, Rhode Island, United States
🇺🇸Morton Plant Hospital, Clearwater, Florida, United States
🇺🇸Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- Conditions
- Stage I Uterine Corpus Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Diagnostic ImagingProcedure: Excisional BiopsyProcedure: Minimally Invasive SurgeryProcedure: Pelvic LymphadenectomyOther: Questionnaire AdministrationProcedure: Sentinel Lymph Node Mapping
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 428
- Registration Number
- NCT05646316
- Locations
- 🇺🇸
Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
- Conditions
- Locally Advanced Lung Non-Small Cell CarcinomaStage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8
- Interventions
- Procedure: Computed TomographyRadiation: Image Guided Radiation TherapyProcedure: Positron Emission TomographyOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT05624996
- Locations
- 🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
- Conditions
- Metastatic Malignant Neoplasm in the Brain
- Interventions
- Procedure: Brain SurgeryOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Radiosurgery
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 236
- Registration Number
- NCT05438212
- Locations
- 🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
- Conditions
- Unresectable Salivary Gland CarcinomaRecurrent Salivary Gland CarcinomaStage IV Major Salivary Gland Cancer AJCC v8Stage III Major Salivary Gland Cancer AJCC v8Metastatic Salivary Gland Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingOther: Questionnaire AdministrationProcedure: Multigated Acquisition Scan
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 146
- Registration Number
- NCT05408845
- Locations
- 🇺🇸
Kaiser Permanente-Roseville, Roseville, California, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
- Conditions
- Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Unresectable Renal Cell Carcinoma
- Interventions
- Radiation: Stereotactic Ablative Radiotherapy
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 240
- Registration Number
- NCT05327686
- Locations
- 🇺🇸
Central Maryland Radiation Oncology in Howard County, Columbia, Maryland, United States
🇺🇸UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie, Maryland, United States
🇺🇸Beverly Hospital, Beverly, Massachusetts, United States
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Conditions
- Stage III Colon Cancer
- Interventions
- Device: Signatera testDrug: mFOLFOX6 6 monthDrug: mFOLFIRINOXDrug: mFOLFOX6 3-6 monthDrug: CAPOX 3 monthDrug: CAPOX 6 month
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 1912
- Registration Number
- NCT05174169
- Locations
- 🇺🇸
Caro Cancer Center, Caro, Michigan, United States
🇺🇸Greater Dayton Cancer Center, Kettering, Ohio, United States
🇺🇸Chelsea Hospital, Chelsea, Michigan, United States
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
- Conditions
- GlioblastomaGliosarcoma
- Interventions
- Procedure: Magnetic Resonance ImagingRadiation: Photon Beam Radiation TherapyOther: Questionnaire Administration
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 306
- Registration Number
- NCT05095376
- Locations
- 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States